Sunshine End Period Cash Flow from 2010 to 2024

SBFMW Stock  USD 0.17  0.04  19.05%   
Sunshine Biopharma End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. During the period from 2010 to 2024, Sunshine Biopharma End Period Cash Flow regression line of quarterly data had mean square error of 31.1 T and geometric mean of  292,249. View All Fundamentals
 
End Period Cash Flow  
First Reported
2007-09-30
Previous Quarter
11.5 M
Current Value
12.2 M
Quarterly Volatility
9.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Sunshine Biopharma Warrant over the last few years. It is Sunshine Biopharma's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Sunshine End Period Cash Flow Regression Statistics

Arithmetic Mean3,934,346
Geometric Mean292,249
Coefficient Of Variation193.04
Mean Deviation5,789,695
Median115,216
Standard Deviation7,594,801
Sample Variance57.7T
Range21.8M
R-Value0.71
Mean Square Error31.1T
R-Squared0.50
Significance0
Slope1,200,485
Total Sum of Squares807.5T

Sunshine End Period Cash Flow History

202417.1 M
202316.3 M
202221.8 M
2021M
2020989.9 K
201940.5 K
2018115.2 K

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow16.3 M17.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.